BACE1-AS non-coding RNA increases apoptosis in HAOEC endothelial cells

Authors
M. Sadeghizadeh 1
I. Sadeghi 1
B. Bakhshinejad 1
H. Moradi Rehabdarkolaee 2
M. Sadeghizadeh 1
1 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Statistical Sciences and Operations Research, Virginia Commonwealth University, Richmond, VA 23284, U.S.A
Abstract
Objective: Heart failure is one of the most common types of cardiac diseases with high rate of morbidity and mortality, which places a large burden on society. Despite well care system, the survival rate for end-stage heart failure patients is less than 1%. Several studies have recently shown a significant association between long non-coding RNAs with different cardiac diseases.
Methods: We investigated the functional mechanism of BACE1-AS, which was previously reported to be up-regulated in heart failure patients, by assessments of gene expression analysis, cell proliferation, and apoptosis.
Results: BACE1-AS down-regulation significantly reduced expressions of cyclin inhibitors that included CDKN1A, CDKN1B, CDKN1C, CDKN2A, and CDKN2B with the exception of CDKN2C and CDKN2D. BACE1-AS over-expression increased expressions of these cell cycle genes, which implied an effect of BACE1-AS LncRNA on the cell cycle. BACE1-AS down-regulation decreased BCL-2 mRNA expression and increased BAX gene expression. BACE1-AS up-regulation increased BCL-2 and reduced BAX expressions. We did not observe any significant change in cell proliferation with BACE1-AS down-regulation, while BACE1-AS up-regulation decreased cell numbers and induced apoptosis compared with the control group (cells treated with an empty vector).
Conclusion: These results showed the important role of BACE1-AS in cell death and, accordingly, pathogenesis of heart failure. It could be considered a potential biomarker for targeting and treatment of heart failure.

Keywords

[1]  Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): e69-171.
[2]  Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104(4): 557-67.
[3]  Morita H, DePalma SR, Arad M, McDonough B, Barr S, Duffy C, Maron BJ, Seidman CE, Seidman JG. Molecular epidemiology of hypertrophic cardiomyopathy. Cold Spring Harb Symp Quant Biol 2002; 67: 383-8.
[4]  Mitra SA, Mitra AP, Triche TJ. A central role for long non-coding RNA in cancer. Front Genet 2012; 3: 17.
[5]  Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Molecular Cell 2011; 43(6): 904-14.
[6]  Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10(3): 155-9.
[7]  Cole SL, Vassar R. The basic biology of BACE1: A key therapeutic target for Alzheimer's disease. Curr Genomics 2007; 8(8): 509-30.
[8]  Cole SL, Vassar R. Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. Neurobiol Aging 2009; 30(10): 1535-44.
[9]  Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, Gatsiou A, Sopova K, Kotakos C, Varounis C, Tellis CC, Kastritis E, Alevizaki M, Tselepis AD, Alexopoulos P, Laske C, Keller T, Kastrati A, Dimmeler S, Zeiher AM, Stellos K. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol 2015; 65(9): 904-16.
[10]  Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997; 3(9): 1016-20.
[11]   Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St Laurent G 3rd, Kenny PJ, Wahlestedt C. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008; 14(7): 723-30.
[12]  Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, St-Laurent G 3rd, Wahlestedt C. Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 2010; 11(5): R56.
[13]  Yan R, Vassar R2. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014; 13(3): 319-29.
[14] Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001; 21(19): 7551-60.
[15]  Kihiko ME, Tucker HM, Rydel RE, Estus S. c-Jun contributes to amyloid beta-induced neuronal apoptosis but is not necessary for amyloid beta-induced c-jun induction. J Neurochem 1999; 73(6): 2609-12.
[16] Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, Masutani H, Yodoi J, Urano Y, Nagano T, Ichijo H. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 2005; 12(1): 19-24.
[17]  Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326(6112): 515-7.
[18]  Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75(4): 805-16.
[19]  Frasca G, Chiechio S, Vancheri C, Nicoletti F, Copani A, Angela Sortino M. Beta-amyloid-activated cell cycle in SH-SY5Y neuroblastoma cells: correlation with the MAP kinase pathway. J Mol Neurosci 2004; 22(3): 231-6.
[20]  Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335(6189): 440-2.
[21]  Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7(3): 279-96.
[22]  Martinet W, Knaapen MW, Kockx MM, De Meyer GR. Autophagy in cardiovascular disease. Trends Mol Med 2007; 13(11): 482-91.
[23]  Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8(9): 741-52.
[24]  Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005; 121(5): 671-4.
Pathobiology Reserach
Volume 20, Issue 4
December 2018
Pages 53-66